Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian Neil Fleming, Morag Hogben, Sheelagh Frame, Steven J McClue, Simon R Green

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.
Original languageEnglish
Pages (from-to)4326-4335
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number13
DOIs
Publication statusPublished - 2008

Fingerprint

Cyclin-Dependent Kinases
ErbB Receptors
roscovitine

Keywords

  • Animals
  • Antineoplastic Agents
  • Cell Line, Tumor
  • Cyclin D1
  • Drug Synergism
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • Models, Biological
  • Mutation
  • Neoplasm Transplantation
  • Purines
  • Receptor, erbB-2

Cite this

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. / Fleming, Ian Neil; Hogben, Morag; Frame, Sheelagh; McClue, Steven J; Green, Simon R.

In: Clinical Cancer Research, Vol. 14, No. 13, 2008, p. 4326-4335.

Research output: Contribution to journalArticle

Fleming, Ian Neil ; Hogben, Morag ; Frame, Sheelagh ; McClue, Steven J ; Green, Simon R. / Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 13. pp. 4326-4335.
@article{f54e4584315c4945b73ec81654f807fc,
title = "Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents",
abstract = "The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.",
keywords = "Animals, Antineoplastic Agents, Cell Line, Tumor, Cyclin D1, Drug Synergism, Female, Gene Expression Regulation, Neoplastic, Humans, Inhibitory Concentration 50, Mice, Models, Biological, Mutation, Neoplasm Transplantation, Purines, Receptor, erbB-2",
author = "Fleming, {Ian Neil} and Morag Hogben and Sheelagh Frame and McClue, {Steven J} and Green, {Simon R}",
year = "2008",
doi = "10.1158/1078-0432.CCR-07-4633",
language = "English",
volume = "14",
pages = "4326--4335",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

AU - Fleming, Ian Neil

AU - Hogben, Morag

AU - Frame, Sheelagh

AU - McClue, Steven J

AU - Green, Simon R

PY - 2008

Y1 - 2008

N2 - The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

AB - The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.

KW - Animals

KW - Antineoplastic Agents

KW - Cell Line, Tumor

KW - Cyclin D1

KW - Drug Synergism

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Inhibitory Concentration 50

KW - Mice

KW - Models, Biological

KW - Mutation

KW - Neoplasm Transplantation

KW - Purines

KW - Receptor, erbB-2

U2 - 10.1158/1078-0432.CCR-07-4633

DO - 10.1158/1078-0432.CCR-07-4633

M3 - Article

VL - 14

SP - 4326

EP - 4335

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -